SI SHOULDER INNOVATIONS, INC.
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1699350 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY54.9%
TTM net income YoY8.3%
TTM EPS YoY102.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin77.8%
Operating margin-54.4%
Net margin-51.7%
FCF margin-66.2%
EBITDA margin-47.9%
Returns
ROE-25.1%
ROA-20.6%
ROIC (approx.)-27.1%
Asset turnover0.40x
Leverage & solvency
Liabilities / assets18.6%
Debt / equity0.13x
Current ratio10.68x
Interest coverage15.44x
Cash quality & payout
Operating cash flow / net income1.05x
Accruals ratio1.0%
Payout ratio—
Capex / revenue12.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $16.19M | $17.18M | $16.71M | $14.42M | $11.76M | $11.01M | $10.13M | $8.72M |
| Cost of revenue | $3.49M | $3.73M | $3.72M | $3.36M | $2.79M | $2.62M | $2.34M | $1.96M |
| Gross profit | $12.71M | $13.44M | $12.99M | $11.06M | $8.96M | $8.39M | $7.79M | $6.77M |
| R&D expense | $3.17M | $3.39M | $3.75M | $3.22M | $1.52M | $1.41M | $1.58M | $1.17M |
| SG&A expense | $17.14M | $20.09M | $18.21M | $16.34M | $15.08M | $12.85M | $10.50M | $9.14M |
| Operating income | -$7.60M | -$10.04M | -$8.98M | -$8.50M | -$7.64M | -$5.86M | -$4.29M | -$3.54M |
| Interest expense | -$574,000 | -$673,000 | -$436,000 | -$591,000 | $78,000 | $216,000 | $367,000 | $391,000 |
| Pretax income | -$7.05M | -$10.15M | -$8.38M | -$7.77M | -$8.73M | -$19.20M | -$4.66M | -$3.79M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$7.05M | -$10.15M | -$8.38M | -$7.77M | -$8.73M | -$19.20M | -$4.66M | -$3.79M |
| EBITDA | -$6.48M | -$8.93M | -$7.92M | -$7.59M | -$6.87M | -$5.22M | -$3.70M | -$2.99M |
| EPS (basic) | -0.34 | -0.49 | -0.41 | — | -0.64 | -165.53 | -52.13 | — |
| EPS (diluted) | -0.34 | -0.49 | -0.41 | — | -0.64 | -165.53 | -52.13 | — |
| Weighted avg. shares (diluted) | 20.84M | 20.74M | 20.65M | — | 13.60M | 115,965 | 89,438 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $36.42M | $24.46M | $11.49M | $26.87M | $54.93M | $27.05M | $6.37M | $6.12M |
| Short-term investments | $55.92M | $74.53M | $97.05M | $97.43M | $82.35M | $12.58M | — | $8.92M |
| Receivables | $9.29M | $10.87M | $10.55M | $8.27M | $7.08M | $6.89M | — | $5.12M |
| Inventory | $24.38M | $22.92M | $21.83M | $21.59M | $19.36M | $17.08M | — | $13.96M |
| Current assets | $131.08M | $137.41M | $145.78M | $157.16M | $166.61M | $68.91M | — | $35.12M |
| PP&E, net | $13.77M | $14.50M | $14.47M | $12.53M | $10.85M | $8.51M | — | $7.49M |
| Intangibles | $14,000 | $0 | $25,000 | $100,000 | $175,000 | $250,000 | — | $400,000 |
| Total assets | $145.57M | $152.01M | $160.36M | $169.91M | $177.76M | $77.83M | — | $43.08M |
| Current liabilities | $12.28M | $12.83M | $12.34M | $14.20M | $15.02M | $12.49M | — | $7.65M |
| Long-term debt | $14.85M | $14.81M | $14.96M | $14.91M | $14.85M | $14.78M | — | $14.66M |
| Total debt | $14.85M | $14.81M | $14.96M | $14.91M | $14.85M | $14.78M | — | $14.66M |
| Total liabilities | $27.15M | $27.68M | $27.34M | $29.16M | $29.93M | $29.33M | — | $23.30M |
| Shareholders' equity | $118.43M | $124.33M | $133.02M | $140.75M | $147.83M | -$78.20M | -$59.31M | -$54.70M |
| Net debt | -$21.57M | -$9.65M | $3.47M | -$11.96M | -$40.09M | -$12.27M | — | $8.54M |
| Shares outstanding | 20.92M | 20.82M | 20.70M | 20.62M | 20.58M | 2.84M | — | 83,882 |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.39M | -$7.39M | -$12.36M | -$8.78M | -$8.55M | -$4.80M | -$6.48M | -$3.27M |
| Capital expenditure | $586,000 | $2.16M | $2.73M | $2.28M | $2.81M | $1.47M | $843,000 | $1.04M |
| Free cash flow | -$6.98M | -$9.55M | -$15.09M | -$11.06M | -$11.37M | -$6.26M | -$7.32M | -$4.32M |
| Investing cash flow | $18.13M | $20.44M | -$3.12M | -$17.28M | -$72.44M | $7.19M | -$13.07M | $3.65M |
| Financing cash flow | $215,000 | -$84,000 | $101,000 | -$2.00M | $108.87M | $18.29M | $19.79M | $0 |
| Depreciation & amortization | $1.12M | $1.11M | $1.06M | $905,000 | $768,000 | $643,000 | $593,000 | $544,000 |
| Stock-based compensation | $1.02M | $1.08M | $726,000 | $381,000 | $298,000 | $190,000 | $127,000 | $179,000 |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.